TRPV6

TRPV6 is a highly Ca²⁺-selective epithelial channel that mediates apical Ca²⁺ entry during transcellular intestinal calcium absorption^[1]. Mechanistically, TRPV6 supports calcium homeostasis under calcium restriction and contributes to bone mineralization in mouse models^[2]. In disease research, TRPV6 variants disrupt maternal-fetal calcium transport in transient neonatal hyperparathyroidism and associate with early-onset chronic pancreatitis^[3]^[4]. Compared with TRPV5, TRPV6 shares epithelial Ca²⁺-channel properties but shows broader tissue distribution, whereas TRPV5 is mainly linked to renal Ca²⁺ reabsorption^[5]. In cancer models, TRPV6 expression correlates with prostate cancer progression, supports prostate cancer cell survival through Orai1-dependent plasma-membrane trafficking, and represents a target in estrogen receptor-negative breast cancer^[6]^[7]^[8]. For experimental applications, TRPV6 antagonists include SOR-C13/SOR-C27 peptides for detecting TRPV6-rich tumors, SOR-C13 evaluated in a phase I solid-tumor trial, and PCHPD inhibitors that block TRPV6 with nanomolar affinity^[9]^[10]^[11].

References:

[1]. Peng JB, et al. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem. 1999 Aug 6;274(32):22739-46. [Content Brief]

[2]. Lieben L, et al. Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis. Bone. 2010 Aug;47(2):301-8. [Content Brief]

[3]. Suzuki Y, et al. TRPV6 Variants Interfere with Maternal-Fetal Calcium Transport through the Placenta and Cause Transient Neonatal Hyperparathyroidism. Am J Hum Genet. 2018 Jun 7;102(6):1104-1114. [Content Brief]

[4]. Masamune A, et al. Variants That Affect Function of Calcium Channel TRPV6 Are Associated With Early-Onset Chronic Pancreatitis. Gastroenterology. 2020 May;158(6):1626-1641.e8. [Content Brief]

[5]. van Abel M, et al. The epithelial calcium channels TRPV5 and TRPV6: regulation and implications for disease. Naunyn Schmiedebergs Arch Pharmacol. 2005 Apr;371(4):295-306. [Content Brief]

[6]. Fixemer T, et al. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene. 2003 Oct 30;22(49):7858-61. [Content Brief]

[7]. Raphaël M, et al. TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3870-9. [Content Brief]

[8]. Peters AA, et al. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther. 2012 Oct;11(10):2158-68. [Content Brief]

[9]. Bowen CV, et al. In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866. [Content Brief]

[10]. Fu S, et al. First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):324-333. [Content Brief]

[11]. Bhardwaj R, et al. Inactivation-mimicking block of the epithelial calcium channel TRPV6. Sci Adv. 2020 Nov 27;6(48):eabe1508. [Content Brief]

TRPV6 Related Products (4):

By Type:	Pan (2)
By Effects:	Inhibitor (1) Antagonists (3)

Cat. No.	Product Name	Effect	Purity

HY-P1651

SOR-C13	Antagonist	99.12%
SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity.

HY-P1651A

SOR-C13 TFA	Antagonist	99.32%
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.

HY-P1651B

SOR-C13 acetate	Antagonist	99.11%
SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC₅₀ of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model.

HY-157574

TRPV6-IN-1	Inhibitor	99.1%
TRPV6-IN-1 is a potent and selective TRPV6 inhibitor. TRPV6-IN-1 has anti-proliferative effect and can be used for the research of cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.